Novartis secures FDA approval for Cosentyx in polymyalgia rheumatica after Phase III REPLENISH results showed doubled sustained remission rates versus placebo.
Written By: Neha Vishwakarma, PharmD
Reviewed By: Pharmacally Editorial Team
Novartis has secured US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering. The decision makes Cosentyx the first and only anti-interleukin-17A (IL-17A) biologic approved for PMR and follows positive results from the Phase III REPLENISH trial, in which secukinumab doubled sustained remission rates compared with placebo at Week 52.
REPLENISH demonstrated sustained remission after steroid tapering
The regulatory approval is based on the global Phase III REPLENISH trial (NCT05767034), a randomized, double-blind, placebo-controlled study conducted across 27 countries. The trial enrolled 381 adults with relapsing PMR and randomized them 1:1:1 to receive subcutaneous secukinumab 300 mg, secukinumab 150 mg, or placebo alongside a 24-week corticosteroid tapering regimen. Patients received subcutaneous doses at Weeks 0, 1, 2, 3, and 4, followed by maintenance dosing every 4 weeks.
At Week 52, 40.5% of patients receiving secukinumab 150 mg achieved sustained remission—defined as the absence of PMR signs and symptoms from Week 12 through Week 52 without escape or rescue therapy—compared with 20.5% in the placebo group. In the published trial dataset, the 300 mg arm yielded a nearly identical sustained remission rate of 41.2% versus 20.4% for placebo (p<0.001 for both doses), leading regulators to clear the lower 150 mg dose as it delivered comparable efficacy without requiring higher drug exposure.
Key secondary endpoints included complete sustained remission at Week 52, adjusted annual cumulative corticosteroid dose, and time to first use of escape or rescue treatment. In the published Phase III analysis, secukinumab-treated patients required approximately 20% to 23% lower cumulative glucocorticoid exposure over 52 weeks than those on placebo (1,683.2 mg for 150 mg and 1,603.7 mg for 300 mg versus 2,093.0 mg for placebo). The findings were published in the New England Journal of Medicine and presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress.
Safety findings highlight the need for continued monitoring
The overall safety profile observed in REPLENISH remained consistent with the established clinical profile of secukinumab. Serious adverse events occurred in 15.9% of patients receiving the 150 mg dose and 14.2% of those receiving placebo.
Hypersensitivity reactions including eczema, dermatitis, rash, and urticaria were reported more frequently with secukinumab 150 mg than with placebo (14% versus 9%). Urinary tract infections also occurred at a higher rate in the 150 mg cohort (13% versus 7%). One patient in the 150 mg group experienced a serious urinary tract infection, while one patient treated with secukinumab experienced a fatal case of cryptococcal meningitis. Because PMR predominantly affects older adults, opportunistic infections and hypersensitivity events remain important clinical considerations when evaluating the benefit-risk profile of IL-17A blockade.
IL-17A inhibition expands options beyond corticosteroids and IL-6 blockade
Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a pro-inflammatory cytokine implicated in the vascular and synovial inflammation driving PMR. For prescribing in PMR, Cosentyx 150 mg is administered via subcutaneous injection using a loading schedule at Weeks 0, 1, 2, 3, and 4, followed by maintenance injections every 4 weeks.
PMR primarily affects adults aged 50 years and older, causing acute pain and stiffness in the shoulders, neck, and hips. While oral corticosteroids remain standard first-line therapy, disease relapses affect up to 40% of patients within the first year, and prolonged steroid exposure elevates the risk of osteoporosis, diabetes, and cardiovascular complications. Prior to this decision, Sanofi and Regeneron’s IL-6 receptor antagonist Kevzara (sarilumab)—approved by the FDA in February 2023 was the only targeted biologic available for PMR. Cosentyx introduces a distinct mechanism of action for patients who fail or cannot tolerate corticosteroid tapering.
Eleventh US indication strengthens Cosentyx’s immunology footprint
The PMR clearance represents the 11th FDA-approved indication for Cosentyx, extending its reach across immune-mediated inflammatory conditions alongside plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. Novartis has also secured European Commission approval for the PMR indication and has submitted regulatory applications in additional markets, including Japan.
By adding a second biologic class alongside IL-6 inhibition, the approval broadens targeted therapeutic options in a disease area historically reliant on chronic glucocorticoid therapy. However, long-term real-world durability of remission and cumulative steroid-sparing outcomes in older patient populations will remain key benchmarks in routine clinical practice.
Reference
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR), Novartis, 17 November 2026
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination with Glucocorticoid Taper Regimen, in Patients with Polymyalgia Rheumatica (PMR) (REPLENISH), ClinicalTrials.gov ID NCT05767034
John H. Stone, M.D., M.P.H et al, Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica, N Engl J Med 2026;395:637-647, DOI: 10.1056/NEJMoa2602567
About the Writer
Neha Vishwakarma (LinkedIn) is a Pharm.D professional with experience in clinical pharmacy, pharmacovigilance, and clinical research. She has hands-on experience in ADR assessment, ICSR processing, medication safety, and clinical data evaluation. Her research background in surgical site infections and antibiotic use supports her focus on evidence-based healthcare writing.
